Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

NCT05877404 | Terminated DMC

• 4 other identifiers: IRB00097221WFBCCC 99323P30CA012197NCI-2023-05554
• Study Type: observational
• Target: 112
• Locations: 1 country
• Sites: 1

Brief Summary

In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.

Conditions

Endometrial Cancer

Keywords

Genetic testing

Outcome Measures

Primary Outcomes (1)

• Percentage of providers reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients

  The primary outcome is to estimate the percentage of providers who report the use of different tumor testing strategies. Investigators will calculate the frequencies of responses to each testing strategy and then compare the percentage of physicians who choose different strategies, using a chi-square or Fisher's exact test.

  4 months

Secondary Outcomes (3)

• Frequency of providers using different strategies of informed consent in tumor genetic testing in endometrial cancer

  4 months

• Number of providers reporting confidence in utilizing tumor genetic testing to guide treatment decisions

  4 months

• Number of providers who change their counseling or testing strategies for endometrial cancer

  4 months

Study Arms (1)

Gynecologic Oncologists

Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).

Other: Surveys

Interventions

Surveys OTHER

Survey on practice patterns surrounding tumor genetic testing in endometrial cancer.

Gynecologic Oncologists

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Gynecologic Oncologists and gynecologic oncology fellows-in-training from around the world, who are members of the Society of Gynecologic Oncology (SGO).

You may qualify if:

• Member of the Society of Gynecologic Oncology
• Gynecologic Oncologist or Gynecologic Oncology Fellow-in-Training

Sponsors & Collaborators

• Wake Forest University Health Sciences: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Endometrial Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Kathryn Weaver, PhD, MPH

  Wake Forest Baptist Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 17, 2023
• First Posted: May 26, 2023
• Study Start: August 15, 2023
• Primary Completion: February 28, 2024
• Study Completion: February 28, 2024
• Last Updated: April 19, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)